A detailed history of Northern Trust Corp transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 310,440 shares of BMEA stock, worth $2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
310,440
Previous 211,952 46.47%
Holding current value
$2 Million
Previous $953,000 228.96%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$4.23 - $10.1 $416,604 - $994,728
98,488 Added 46.47%
310,440 $3.14 Million
Q2 2024

Aug 14, 2024

SELL
$4.14 - $15.3 $18,596 - $68,727
-4,492 Reduced 2.08%
211,952 $953,000
Q1 2024

May 14, 2024

SELL
$13.92 - $19.5 $82,517 - $115,596
-5,928 Reduced 2.67%
216,444 $3.24 Million
Q4 2023

Feb 13, 2024

BUY
$8.37 - $19.8 $311,506 - $736,896
37,217 Added 20.1%
222,372 $3.23 Million
Q3 2023

Nov 13, 2023

BUY
$13.44 - $23.02 $54,660 - $93,622
4,067 Added 2.25%
185,155 $2.55 Million
Q2 2023

Aug 11, 2023

BUY
$21.66 - $41.8 $3.25 Million - $6.27 Million
149,882 Added 480.3%
181,088 $3.97 Million
Q1 2023

May 15, 2023

BUY
$6.8 - $32.35 $12,614 - $60,009
1,855 Added 6.32%
31,206 $967,000
Q3 2022

Nov 14, 2022

BUY
$9.51 - $13.61 $117,039 - $167,498
12,307 Added 72.21%
29,351 $287,000
Q2 2022

Aug 12, 2022

SELL
$3.0 - $12.03 $448,200 - $1.8 Million
-149,400 Reduced 89.76%
17,044 $205,000
Q1 2022

May 13, 2022

SELL
$4.39 - $9.03 $32,942 - $67,761
-7,504 Reduced 4.31%
166,444 $742,000
Q4 2021

Feb 08, 2022

BUY
$7.22 - $12.72 $661,648 - $1.17 Million
91,641 Added 111.34%
173,948 $1.3 Million
Q3 2021

Nov 15, 2021

SELL
$10.0 - $15.99 $72,850 - $116,487
-7,285 Reduced 8.13%
82,307 $985,000
Q2 2021

Aug 13, 2021

BUY
$13.65 - $20.93 $1.22 Million - $1.88 Million
89,592 New
89,592 $1.4 Million

Others Institutions Holding BMEA

About Biomea Fusion, Inc.


  • Ticker BMEA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,290,600
  • Market Cap $189M
  • Description
  • Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...
More about BMEA
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.